SEARCH

SEARCH BY CITATION

REFERENCES

  • Aicardi G,Argilli E,Cappello S,Santi S,Riccio M,Thoenen H,Canossa M. 2004. Induction of long-term potentiation and depression is reflected by corresponding changes in secretion of endogenous brain-derived neurotrophic factor. Proc Natl Acad Sci USA 101: 1578815792.
  • Alexander GE,Chen K,Pietrini P,Rapoport SI,Reiman EM. 2002. Longitudinal PET evaluation of cerebral metabolic decline in Dementia: A potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 159: 738745.
  • Bankiewicz KS,Forsayeth J,Eberling JL,Sanchez-Pernaute R,Pivirotto P,Bringas J,Herscovitch P,Carson RE,Eckelman W,Reutter B,Cunningham J. 2006. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 14: 564570.
  • Blesch A,Pfeiffer A,Conner JM,Britton W,Verma I,Tuszynski MH. 2005. Regulated lentiviral NGF genetransfer controls rescue of medial septal cholinergic neurons. Mol Ther 11: 916925.
  • Boissiere F,Hunot S,Faucheux B,Hersh LB,Agid Y,Hirsch EC. 1997. Trk neurotrophin receptors in cholinergic neurons of patients with Alzheimer's disease. Dement Geriatr Cogn Disord 8: 18.
  • Campenot RB,MacInnis BL. 2004. Retrograde transport of neurotrophins: Fact and function. J Neurobiol 58: 217229.
  • Candy JM,Perry RH,Perry EK,Irving D,Blessed G,Fairbairn AF,Tomlinson BE. 1983. Pathological changes in the nucleus basalis of Meynert in Alzheimer's and Parkinson's diseases. J Neurosci 54: 277289.
  • Chen KS,Gage FH. 1995. Somatic gene transfer of NGF to the aged brain: Behavioral and morphological amelioration. J Neurosci 15: 28192825.
  • Choi VW,McCarty DM,Samulski RJ. 2005. AAV hybrid serotypes: Improved vectors for gene delivery. Curr Gene Ther 5: 299310.
  • Chu Y,Cochran EJ,Bennett DA,Mufson EJ,Kordower JH. 2001. Down-regulation of trkA mRNA within nucleus basalis neurons in individuals with mild cognitive impairment and Alzheimer's disease. J Comp Neurol 437: 296307.
  • Conner JM,Chiba AA,Tuszynski MH. 2005. The basal forebrain cholinergic system is essential for cortical plasticity and functional recovery following brain injury. Neuron 46: 173179.
  • Conner JM,Culberson A,Packowski C,Chiba A,Tuszynski MH. 2003. Lesions of the basal forebrain cholinergic system impair task acquisition and abolish cortical plasticity associated with motor skill learning. Neuron 38: 819829.
  • Conner JM,Darracq MA,Roberts J,Tuszynski MH. 2001. Non-tropic actions of neurotrophins: Subcortical NGF gene delivery reverses age-related degeneration of primate cortical cholinergic innervation. Proc Natl Acad Sci 98: 19411946.
  • Cooper JD,Salehi A,Delcroix JD,Howe CL,Belichenko PV,Chua-Couzens J,Kilbridge JF,Carlson EJ,Epstein CJ,Mobley WC. 2001. Failed retrograde transport of NGF in a mouse model of Down's syndrome: Reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci USA 98: 1043910444.
  • Crutcher KA,Scott SA,Liang S,Everson WV,Weingartner J. 1993. Detection of NGF-like activity in human brain tissue: Increased levels in Alzheimer's disease. J Neurosci 13: 25402550.
  • Dai J,Buijs RM,Kamphorst W,Swaab DF. 2002. Impaired axonal transport of cortical neurons in Alzheimer's disease is associated with neuropathological changes. Brain Res 948: 138144.
  • Davis KL,Thal LJ,Gamzu ER,Davis CS,Woolson RF,Gracon SI,Drachman DA,Schneider LS,Whitehouse PJ,Hoover TM. 1992. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. New Engl J Med 327: 12531259.
  • Dawbarn D,Allen SJ,Semenenko FM. 1988. Coexistence of choline acetyltransferase and nerve growth factor receptors in the rat basal forebrain. Neurosci Lett 94: 138144.
  • Dekker AJ,Gage FH,Thal LJ. 1992. Delayed treatment with nerve growth factor improves acquisition of a spatial task in rats with lesions of the nucleus basalis magnocellularis: Evaluation of the involvement of different neurotransmitter systems. Neuroscience 48: 111119.
  • Emerich DW,Winn S,Harper J,Hammang JP,Baetge EE,Kordower JH. 1994. Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: Rescue and sprouting of degenerating cholinergic basal forebrain neurons. J Comp Neurol 349: 148164.
  • Emmett CJ,Stewart GR,Johnson RM,Aswani SP,Chan RL,Jakeman LB. 1996. Distribution of radioiodinated recombinant human nerve growth factor in primate brain following intracerebroventricular infusion. Exp Neurol 140: 151160.
  • Eriksdotter Jonhagen M,Nordberg A,Amberla K,Backman L,Ebendal T,Meyerson B,Olson L,Seiger,Shigeta M,Theodorsson E,Viitanen M,Winblad B,Wahlund LO. 1998. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 9: 246257.
  • Fahnestock M,Scott SA,Jette N,Weingartner JA,Crutcher KA. 1996. Nerve growth factor mRNA and protein levels measured in the same tissue from normal and Alzheimer's disease parietal cortex. Brain Res Mol Brain Res 42: 175178.
  • Fischer W,Wictorin K,Bjorklund A,Williams LR,Varon S,Gage FH. 1987. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 329: 6568.
  • Gash DM,Zhang Z,Ovadia A,Cass WA,Yi A,Simmerman L,Russell D,Martin D,Lapchak PA,Collins F,Hoffer BJ,Gerhardt GA. 1996. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380: 252255.
  • Gill SS,Patel NK,Hotton GR,O'Sullivan K,McCarter R,Bunnage M,Brooks DJ,Svendsen CN,Heywood P. 2003. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9: 589595.
  • Group A-CTS. 1996. A double-blind placebo-controlled trial of subcutaneous recombinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis. Neurology 46: 12441249.
  • Group TBS. 1999. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF STudy Group (Phase III). Neurology 52: 14271433.
  • Grundman M,Thal LJ. 2000. Treatment of Alzheimer's disease: Rationale and strategies. Neurol Clin 18: 807828.
  • Hefti F. 1986. Nerve growth factor (NGF) promotes survival of septal cholinergic neurons after fimbrial transection. J Neurosci 6: 21552162.
  • Hellweg R,Gericke CA,Jendroska K,Hartung HD,Cervos-Navarro J. 1998. NGF content in the cerebral cortex of non-demented patients with amyloid-plaques and in symptomatic Alzheimer's disease. Int J Dev Neurosci 16: 787794.
  • Hock C,Heese K,Hulette C,Rosenberg C,Otten U. 2000. Region-specific neurotrophin imbalances in Alzheimer disease: Decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 57: 846851.
  • Holtzman DM,Li Y,Chen K,Gage FH,Epstein CJ,Mobley WC. 1993. Nerve growth factor reverses neuronal atrophy in a Down syndrome model of age-related neurodegeneration. Neurology 43: 26682673.
  • Holtzman DM,Li Y,Parada LF,Kinsman S,Chen CK,Valletta JS,Zhou J,Long JB,Mobley WC. 1992. p140trk mRNA marks NGF-responsive forebrain neurons: Evidence that trk gene expression is induced by NGF. Neuron 9: 465478.
  • Howe CL,Mobley WC. 2001. Nerve growth factor effects on cholinergic modulation of hippocampal and cortical plasticity. In: MocchettiI, editor. Neurobiology of the Neurotrophins. Johnson City, TN: F.P. Graham Publishing.
  • Howe CL,Mobley WC. 2004. Signaling endosome hypothesis: A cellular mechanism for long distance communication. J Neurobiol 58: 207216.
  • Hu L,Cote SL,Cuello AC. 1997. Differential modulation of the cholinergic phenotype of the nucleus basalis magnocellularis neurons by applying NGF at the cell body or cortical terminal fields. Exp Neurol 143: 162171.
  • Isaacson LG,Saffran BN,Crutcher KA. 1990. Intracerebral NGF infusion induces hyperinnervation of cerebral blood vessels. Neurobiol Aging 11: 5155.
  • Kaplan DR,Miller FD. 2000. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 10: 381391.
  • Kiss J,McGovern J,Patel AJ. 1988. Immunohistochemical localization of cells containing nerve growth factor receptors in the different regions of the adult rat forebrain. Neurosci Lett 27: 731748.
  • Klein RL,Hirko AC,Meyers CA,Grimes JR,Muzyczka N,Meyer EM. 2000. NGF gene transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats. Brain Res 875: 144151.
  • Koliatsos VE,Clatterbuck RE,Nauta HJ,Knusel B,Burton LE,Hefti FF,Mobley WC,Price DL. 1991. Human nerve growth factor prevents degeneration of basal forebrain cholinergic neurons in primates. Ann Neurol 30: 831840.
  • Kordower JH,Emborg ME,Bloch J,Ma SY,Chu Y,Leventhal L,McBride J,Chen EY,Palfi S,Roitberg BZ,Brown WD,Holden JE,Pyzalski R,Taylor MD,Carvey P,Ling Z,Trono D,Hantraye P,Déglon N,Aebischer P. 2000. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290: 767773.
  • Kordower JH,Palfi S,Chen EY,Ma SY,Sendera T,Cochran EJ,Cochran EJ,Mufson EJ,Penn R,Goetz CG,Comella CD. 1999. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 46: 419424.
  • Kordower JH,Winn SR,Liu Y-T,Mufson EJ,Sladek JR,Hammang JP,Baetge EE,Emerich DF. 1994. The aged monkey basal forebrain: Rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor. Proc Natl Acad Sci USA 91: 1089810902.
  • Korsching S,Auburger G,Heumann R,Scott J,Thoenen H. 1985. Levels of nerve growth factor and its mRNA in the central nervous system of the rat correlate with cholinergic innervation. EMBO J 4: 13891393.
  • Kromer LF. 1987. Nerve growth factor treatment after brain injury prevents neuronal death. Science 235: 214216.
  • Levi-Montalcini R. 1987. The nerve growth factor 35 years later. Science 237: 11541162.
  • Levi-Montalcini R,Hamburger V. 1951. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J Exp Zool 116: 321362.
  • Levi-Montalcini R,Hamburger Y. 1953. A diffusible agent of mouse sarcoma, producing hyperplasia of sympathetic ganglia and hyperneurotization of viscera in the chick embryo. J Exp Zool 123: 233288.
  • Levi-Montalcini R,Meyer H,Hamburger V. 1954. In vitro experiments on the effects of mouse sarcoma 180 and 37 on the spinal and sympathetic ganglia of the chick embryo. Cancer Res 14: 4957.
  • Liberini P,Pioro EP,Maysinger D,Ervin FR,Cuello AC. 1993. Long-term protective effects of human recombinant nerve growth factor and monosialoganglioside GM1 treatment on primate nucleus basalis cholinergic neurons after neocortical infarction. Neuroscience 53: 625637.
  • Mahadeo D,Kaplan L,Chao MV,Hempstead BL. 1994. High affinity nerve growth factor binding displays a faster rate of association than p140trk binding. Implications for multisubunit polypedtide receptors. J Biol Chem 269: 68846891.
  • Mandelkow EM,Stamer K,Vogel R,Thies E,Mandelkow E. 2003. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 24: 10791085.
  • Markowska AL,Koliatsos VE,Breckler SJ,Price DL,Olton DS. 1994. Human nerve growth factor improves spatial memory in aged but not in young rats. J Neurosci 14: 48154824.
  • Masliah E,Terry RD,Alford M,DeTeresa R,Hansen LA. 1991. Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease. Am J Pathol 138: 235246.
  • Miller FD,Kaplan DR. 2001. Neurotrophin signalling pathways regulating neuronal apoptosis. Curr Opin Neurobiol 11: 297305.
  • Mufson EJ,Bothwell M,Kordower JH. 1989. Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: A quantitative analysis across subregions of the basal forebrain. Exp Neurol 105: 221232.
  • Mufson EJ,Conner JM,Kordower JH. 1995. Nerve growth factor in Alzheimer's disease: Defective retrograde transport to nucleus basalis. Neuroreport 6: 10631066.
  • Mufson EJ,Ginsberg SD,Ikonomovic MD,DeKosky ST. 2003a. Human cholinergic basal forebrain: Chemoanatomy and neurologic dysfunction. J Chem Neuroanat 26: 233242.
  • Mufson EJ,Ikonomovic MD,Styren SD,Counts SE,Wuu J,Leurgans S,Bennett DA,Cochran EJ,DeKosky ST. 2003b. Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease. Arch Neurol 60: 11431148.
  • Mufson EJ,Lavine N,Jaffar S,Kordower JH,Quirion R,Saragovi HU. 1997. Reduction in p140-TrKA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. ExpNeurol 146: 91103.
  • Mufson EJ,Ma SY,Dills J,Cochran EJ,Leurgans S,Wuu J,Bennett DA,Jaffar S,Gilmor ML,Levey Al,Kordower JH. 2002. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol 443: 136153.
  • Narisawa-Saito M,Wakabayashi K,Tsuji S,Takahashi H,Nawa H. 1996. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. Neuroreport 7: 29252928.
  • Nutt JG,Burchiel KJ,Comella CL,Jankovic J,Lang AE,Laws ERJr,Lozano AM,Penn RD,Simpson RKJr,Stacy M,Wooten GF. 2003. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60: 6973.
  • Perry EK,Curtis M,Dick DJ,Candy JM,Atack JR,Bloxham CA,Blessed G,Fairbairn A,Tomlinson BE,Perry RH. 1985. Cholinergic correlates of cognitive impairment in Parkinson's disease: Comparison with Alzheimer's disease. J Neurol Neurosurg Psychiatry 48: 413421.
  • Perry EK,Tomlinson BE,Blessed G,Bergmann K,Gibson PH,Perry RH. 1978. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2: 14571459.
  • Potkin SG,Anand R,Alva G,Fallon JH,Keator D,Carreon D,Messina J,Wu JC,Hartman R,Fleming K. 2001. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int J Neuropsychopharm 4: 223230.
  • Ridley RM,Baker HF,Leow-Dyke A,Cummings RM. 2005. Further analysis of the effects of immunotoxic lesions of the basal nucleus of Meynert reveals substantial impairment on visual discrimination learning in monkeys. Brain Res Bull 65: 433442.
  • Rosenberg MB,Friedmann T,Robertson RC,Tuszynski M,Wolff JA,Breakefield XO,Gage FH. 1988. Grafting genetically modified cells to the damaged brain: Restorative effects of NGF expression. Science 242: 15751578.
  • Salehi A,Delcroix JD,Belichenko PV,Zhan K,Wu C,Valletta JS,Takimoto-Kimura R,Kleschevnikov AM,Sambamurti K,Chung PP,Xia W,Villar A,Campbell WA,Kulnane LS,Nixon RA,Lamb BT,Epstein CJ,Stokin GB,Goldstein LS,Mobley WC. 2006. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51: 2942.
  • Salehi A,Delcroix JD,Swaab DF. 2004. Alzheimer's disease and NGF signaling. J Neural Transm 111: 323345.
  • Savaskan E,Muller-Spahn F,Olivieri G,Bruttel S,Otten U,Rosenberg C,Hulette C,Hock C. 2000. Alterations in trk A,trk B and trk C receptor immunoreactivities in parietal cortex and cerebellum in Alzheimer's disease. Eur Neurol 44: 172180.
  • Scott SA,Mufson EJ,Weingartner JA,Skau KA,Crutcher KA. 1995. Nerve growth factor in Alzheimer's disease: Increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci 15: 62136221.
  • Smith DE,Roberts J,Gage FH,Tuszynski MH. 1999. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc Natl Acad Sci USA 96: 1089310898.
  • Sofroniew MV,Cooper JD,Svendsen CN,Crossman P,Ip NY,Lindsay RM,Zafra F,Lindholm D. 1993. Atrophy but not death of adult septal cholinergic neurons after ablation of target capacity to produce mRNAs for NGF, BDNF, and NT3. J Neurosci 13: 52635276.
  • Sofroniew MV,Galletly NP,Isacson O,Svendsen CN. 1990. Survival of adult basal forebrain cholinergic neurons after loss of target neurons. Science 247: 338342.
  • Sofroniew MV,Howe CL,Mobley WC. 2001. Nerve growth factor signaling,neuroprotection, and neural repair. Annu Rev Neurosci 24: 12171281.
  • Stokin GB,Lillo C,Falzone TL,Brusch RG,Rockenstein E,Mount SL,Raman R,Davies P,Masliah E,Williams DS,Goldstein LS. 2005. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307: 12821288.
  • Tuszynski MH. 1999. Neurotrophic factors. In: M.H.a.K TuszynskiJH,editor. CNS Regeneration: Basic Science and Clinical Advances. San Diego: Academic Press, pp 109158.
  • Tuszynski MH. 2002. Gene therapy for neurodegenerative disorders. Lancet Neurol 2002: 5157.
  • Tuszynski MH,Gage FH. 1995. Bridging grafts and transient NGF infusions promote long-term CNS neuronal rescue and partial functional recovery. Proc Natl Acad Sci USA 92: 46214625.
  • Tuszynski MH,Roberts J,Senut MC,U H-S,Gage FH. 1996. Gene therapy in the adult primate brain: Intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Therapy 3: 305314.
  • Tuszynski MH,Thal L,Pay M,Salmon DP,U HS,Bakay R,Patel P,Blesch A,Vahlsing HL,Ho G,Tong G,Potkin SG,Fallon J,Hansen L,Mufson EJ,Kordower JH,Gall C,Conner J. 2005. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11: 551555.
  • Tuszynski MH,U HS,Amaral DG,Gage FH. 1990. Nerve growth factor infusion in primate brain reduces lesion-induced cholinergic neuronal degeneration. J Neurosci 10: 36043614.
  • Tuszynski MH,U H-S,Gage FH. 1991. Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann Neurol 30: 625636.
  • Ullrich A,Gray A,Berman C,Dull TJ. 1983. Human beta-nerve growth factor gene sequence highly homologous to that of mouse. Nature 303: 821825.
  • Verma IM,Weitzman MD. 2005. Gene therapy: Twenty-first century medicine. Annu Rev Biochem 74: 711738.
  • Voytko ML,Olton DS,Richardson RT,Gorman LK,Tobin JR,Price DL. 1994. Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J Neurosci 14: 167186.
  • Wenk GL. 1997. The nucleus basalis magnocellularis cholinergic system: One hundred years of progress. Neurobiol Learn Mem 67: 8595.
  • Whittemore SR,Ebendal T,Larkfors L,Olson L,Seiger A,Stromberg I,Persson H. 1986. Developmental and regional expression of B nerve growth factor messenger RNA and protein in the rat central nervous system. Proc Natl Acad Sci USA 83: 817821.
  • Williams LR. 1991. Hypophagia is induced by intracerebroventricular administration of nerve growth factor. Exp Neurol 113: 3137.
  • Williams LR,Varon S,Peterson GM,Wictorin K,Fisher W,Bjorklund A,Gage FH. 1986. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria-fornix transection. Proc Natl Acad Sci USA 83: 92319235.
  • Winkler J,Ramirez GA,Kuhn HG,Peterson DA,Day-Lollini PA,Stewart GR,Tuszynski MH,Gage FH,Thal LJ. 1997. Reversible Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor. Ann Neurol 41: 8293.